Autocrine motility factor receptor: a clinical review

References

• Arteaga CL, Moulder SL, Yakes FM. HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Semin. Oncol.29(3 Suppl. 11), 4–10 (2002).
   PubMedGoogle Scholar
• Nabi IR, Raz A. Cell shape modulation alters glycosylation of a metastatic melanoma cell-surface antigen. Int. J. Cancer40(3), 396–402 (1987).
   PubMedGoogle Scholar
• Fang S, Ferrone M, Yang C et al. The tumor autocrine motility factor receptor, gp78, is a ubiquitin protein ligase implicated in degradation from the endoplasmic reticulum. Proc. Natl Acad. Sci. USA98(25), 14422–14427 (2001).
   PubMed Web of Science ®Google Scholar
• Onishi Y, Tsukada K, Yokota J, Raz A. Overexpression of autocrine motility factor receptor (AMFR) in NIH3T3 fibroblasts induces cell transformation. Clin. Exp. Metastasis20(1), 51–58 (2003).
   PubMed Web of Science ®Google Scholar
• Tsutsumi S, Hogan V, Nabi IR, Raz A. Overexpression of the autocrine motility factor/phosphoglucose isomerase induces transformation and survival of NIH-3T3 fibroblasts. Cancer Res.63(1), 242–249 (2003).
   PubMed Web of Science ®Google Scholar
• Watanabe H, Nabi IR, Raz A. The relationship between motility factor receptor internalization and the lung colonization capacity of murine melanoma cells. Cancer Res.51(10), 2699–2705 (1991).
   PubMed Web of Science ®Google Scholar
• Korman HJ, Peabody JO, Cerny JC et al. Autocrine motility factor receptor as a possible urine marker for transitional cell carcinoma of the bladder. J. Urol.155(1), 347–349 (1996).
   PubMedGoogle Scholar
• Kara M, Ohta Y, Tanaka Y, Oda M, Watanabe Y. Autocrine motility factor receptor expression in patients with stage I non-small cell lung cancer. Ann. Thorac. Surg.71(3), 944–948 (2001).
   PubMedGoogle Scholar
• Takanami I, Takeuchi K. Autocrine motility factor-receptor gene expression in lung cancer. Jpn. J. Thorac. Cardiovasc. Surg.51(8), 368–373 (2003).
   PubMedGoogle Scholar
• Takanami I, Takeuchi K, Watanabe H et al. Significance of autocrine motility factor receptor gene expression as a prognostic factor in non-small-cell lung cancer. Int. J. Cancer95(6), 384–387 (2001).
   PubMedGoogle Scholar
• Kaynak K, Kara M, Oz B et al. Autocrine motility factor receptor expression implies an unfavourable prognosis in resected stage I pulmonary adenocarcinomas. Acta Chir. Belg.105(4), 378–382 (2005).
   PubMed Web of Science ®Google Scholar
• Maruyama K, Watanabe H, Shiozaki H et al. Expression of autocrine motility factor receptor in human esophageal squamous cell carcinoma. Int. J. Cancer64(5), 316–321 (1995).
   PubMed Web of Science ®Google Scholar
• Hirono Y, Fushida S, Yonemura Y et al. Expression of autocrine motility factor receptor correlates with disease progression in human gastric cancer. Br. J. Cancer74(12), 2003–2007 (1996).
   PubMed Web of Science ®Google Scholar
• Kawanishi K, Doki Y, Shiozaki H et al. Correlation between loss of E-cadherin expression and overexpression of autocrine motility factor receptor in association with progression of human gastric cancers. Am. J. Clin. Pathol.113(2), 266–274 (2000).
   PubMed Web of Science ®Google Scholar
• Nakamori S, Watanabe H, Kameyama M et al. Expression of autocrine motility factor receptor in colorectal cancer as a predictor for disease recurrence. Cancer74(7), 1855–1862 (1994).
   PubMed Web of Science ®Google Scholar
• Ohta Y, Minato H, Tanaka Y et al. Autocrine motility factor receptor expression associates with tumor progression in thymoma. Int. J. Oncol.17(2), 259–264 (2000).
   PubMedGoogle Scholar
• Shimizu K, Tani M, Watanabe H et al. The autocrine motility factor receptor gene encodes a novel type of seven transmembrane protein. FEBS Lett.456(2), 295–300 (1999).
   PubMed Web of Science ®Google Scholar
• Nabi IR, Watanabe H, Raz A. Identification of B16-F1 melanoma autocrine motility-like factor receptor. Cancer Res.50(2), 409–414 (1990).
   PubMed Web of Science ®Google Scholar
• Silletti S, Watanabe H, Hogan V, Nabi IR, Raz A. Purification of B16-F1 melanoma autocrine motility factor and its receptor. Cancer Res.51(13), 3507–3511 (1991).
   PubMedGoogle Scholar
• Watanabe H, Carmi P, Hogan V et al. Purification of human tumor cell autocrine motility factor and molecular cloning of its receptor. J. Biol. Chem.266(20), 13442–13448 (1991).
   PubMed Web of Science ®Google Scholar
• Bodansky O. Serum phosphohexose isomerase in cancer. II. As an index of tumor growth in metastatic carcinoma of the breast. Cancer7(6), 1200–1226 (1954).
   PubMed Web of Science ®Google Scholar
• Schwartz MK. Enzymes in cancer. Clin. Chem.19(1), 10–22 (1973).
   PubMed Web of Science ®Google Scholar
• Liotta LA, Mandler R, Murano G et al. Tumor cell autocrine motility factor. Proc. Natl Acad. Sci. USA83(10), 3302–3306 (1986).
   PubMed Web of Science ®Google Scholar
• Benlimame N, Simard D, Nabi IR. Autocrine motility factor receptor is a marker for a distinct membranous tubular organelle. J. Cell Biol.129(2), 459–471 (1995).
   PubMedGoogle Scholar
• Benlimame N, Le PU, Nabi IR. Localization of autocrine motility factor receptor to caveolae and clathrin-independent internalization of its ligand to smooth endoplasmic reticulum. Mol. Biol. Cell9(7), 1773–1786 (1998).
   PubMed Web of Science ®Google Scholar
• Goetz JG, Nabi IR. Interaction of the smooth endoplasmic reticulum and mitochondria. Biochem. Soc. Trans.34(Pt 3), 370–373 (2006).
   PubMed Web of Science ®Google Scholar
• Wang HJ, Benlimame N, Nabi I. The AMF-R tubule is a smooth ilimaquinone-sensitive subdomain of the endoplasmic reticulum. J. Cell. Sci.110(Pt 24), 3043–3053 (1997).
   PubMedGoogle Scholar
• Ye Y, Shibata Y, Kikkert M et al. Inaugural article: Recruitment of the p97 ATPase and ubiquitin ligases to the site of retrotranslocation at the endoplasmic reticulum membrane. Proc. Natl Acad. Sci. USA102(40), 14132–14138 (2005).
   PubMed Web of Science ®Google Scholar
• Song BL, Sever N, DeBose-Boyd RA. Gp78, a membrane-anchored ubiquitin ligase, associates with Insig-1 and couples sterol-regulated ubiquitination to degradation of HMG CoA reductase. Mol. Cell.19(6), 829–840 (2005).
   PubMed Web of Science ®Google Scholar
• Liang JS, Kim T, Fang S et al. Overexpression of the tumor autocrine motility factor receptor Gp78, a ubiquitin protein ligase, results in increased ubiquitinylation and decreased secretion of apolipoprotein B100 in HepG2 cells. J. Biol. Chem.278(26), 23984–23988 (2003).
   PubMed Web of Science ®Google Scholar
• Lee JN, Song B, DeBose-Boyd RA, Ye J. Sterol-regulated degradation of Insig-1 mediated by the membrane-bound ubiquitin ligase gp78. J. Biol. Chem.281(51), 39308–39315 (2006).
   PubMed Web of Science ®Google Scholar
• Tsai YC, Mendoza A, Mariano JM et al. The ubiquitin ligase gp78 promotes sarcoma metastasis by targeting KAI1 for degradation. Nat. Med.13(12), 1504–1509 (2007).
   PubMed Web of Science ®Google Scholar
• Kojic LD, Joshi B, Lajoie P et al. Raft-dependent endocytosis of autocrine motility factor is phosphatidylinositol 3-kinase-dependent in breast carcinoma cells. J. Biol. Chem.282(40), 29305–29313 (2007).
   PubMedGoogle Scholar
• Le PU, Guay G, Altschuler Y, Nabi IR. Caveolin-1 is a negative regulator of caveolae-mediated endocytosis to the endoplasmic reticulum. J. Biol. Chem.277(5), 3371–3379 (2002).
   PubMedGoogle Scholar
• Le PU, Nabi IR. Distinct caveolae-mediated endocytic pathways target the Golgi apparatus and the endoplasmic reticulum. J. Cell. Sci.116(Pt 6), 1059–1071 (2003).
   PubMed Web of Science ®Google Scholar
• Nabi IR, Le PU. Caveolae/raft-dependent endocytosis. J. Cell Biol.161(4), 673–677 (2003).
   PubMed Web of Science ®Google Scholar
• Lajoie P, Nabi IR. Regulation of raft-dependent endocytosis. J. Cell. Mol. Med.11(4), 644–653 (2007).
   PubMed Web of Science ®Google Scholar
• Kanbe K, Chigira M, Watanabe H. Effects of protein kinase inhibitors on the cell motility stimulated by autocrine motility factor. Biochim. Biophys. Acta.1222(3), 395–399 (1994).
   PubMedGoogle Scholar
• Tsutsumi S, Gupta SK, Hogan V, Collard JG, Raz A. Activation of small GTPase Rho is required for autocrine motility factor signaling. Cancer Res.62(15), 4484–4490 (2002).
   PubMedGoogle Scholar
• Tsutsumi S, Yanagawa T, Shimura T, Kuwano H, Raz A. Autocrine motility factor signaling enhances pancreatic cancer metastasis. Clin. Cancer Res.10(22), 7775–7784 (2004).
   PubMedGoogle Scholar
• Silletti S, Paku S, Raz A. Tumor autocrine motility factor responses are mediated through cell contact and focal adhesion rearrangement in the absence of new tyrosine phosphorylation in metastatic cells. Am. J. Pathol.148(5), 1649–1660 (1996).
   PubMedGoogle Scholar
• Torimura T, Ueno T, Kin M et al. Autocrine motility factor enhances hepatoma cell invasion across the basement membrane through activation of b1 integrins. Hepatology34(1), 62–71 (2001).
   PubMed Web of Science ®Google Scholar
• Timar J, Trikha M, Szekeres K et al. Autocrine motility factor signals integrin-mediated metastatic melanoma cell adhesion and invasion. Cancer Res.56(8), 1902–1908 (1996).
   PubMed Web of Science ®Google Scholar
• Haga A, Funasaka T, Niinaka Y, Raz A, Nagase H. Autocrine motility factor signaling induces tumor apoptotic resistance by regulations Apaf-1 and Caspase-9 apoptosome expression. Int. J. Cancer107(5), 707–714 (2003).
   PubMedGoogle Scholar
• Haga A, Niinaka Y, Raz A. Phosphohexose isomerase/autocrine motility factor/neuroleukin/maturation factor is a multifunctional phosphoprotein. Biochim. Biophys. Acta.1480(1–2), 235–244 (2000).
   PubMed Web of Science ®Google Scholar
• Tamura M, Ohta Y, Oda M, Watanabe G. Peripherally located occult lung cancer with AMFR expression. Ann. Thorac. Cardiovasc. Surg.9(3), 184–187 (2003).
   PubMedGoogle Scholar
• Ohta Y, Tanaka Y, Hara T et al. Clinicopathological and biological assessment of lung cancers with pleural dissemination. Ann. Thorac. Surg.69(4), 1025–1029 (2000).
   PubMedGoogle Scholar
• Taniguchi K, Yonemura Y, Nojima N et al. The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor. Cancer82(11), 2112–2122 (1998).
   PubMed Web of Science ®Google Scholar
• Wang W, Yang LY, Yang ZL, Peng JX, Yang JQ. Elevated expression of autocrine motility factor receptor correlates with overexpression of RhoC and indicates poor prognosis in hepatocellular carcinoma. Dig. Dis. Sci.52(3), 770–775 (2007).
   PubMed Web of Science ®Google Scholar
• Nagai Y, Ishikawa O, Miyachi Y, Watanabe H. Expression of autocrine motility factor receptor in cutaneous malignant melanoma. Dermatology192(1), 8–11 (1996).
   PubMedGoogle Scholar
• Timar J, Raso E, Dome B et al. Expression and function of the AMF receptor by human melanoma in experimental and clinical systems. Clin. Exp. Metastasis19(3), 225–232 (2002).
   PubMed Web of Science ®Google Scholar
• Jiang WG, Raz A, Douglas-Jones A, Mansel RE. Expression of autocrine motility factor (AMF) and its receptor, AMFR, in human breast cancer. J. Histochem. Cytochem.54(2), 231–241 (2006).
   PubMed Web of Science ®Google Scholar
• Otto T, Birchmeier W, Schmidt U et al. Inverse relation of E-cadherin and autocrine motility factor receptor expression as a prognostic factor in patients with bladder carcinomas. Cancer Res.54(12), 3120–3123 (1994).
   PubMed Web of Science ®Google Scholar
• Endo K, Shirai A, Furukawa M, Yoshizaki T. Prognostic value of cell motility activation factors in patients with tongue squamous cell carcinoma. Hum. Pathol.37(8), 1111–1116 (2006).
   PubMedGoogle Scholar
• Wiseman SM, Masoudi H, Niblock P et al. Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann. Surg. Oncol.14(2), 719–729 (2007).
   PubMed Web of Science ®Google Scholar
• Sakamoto H, Nakayama Y, Ohtani K, Seiki M, Satoh K. Pulmonary metastatic lesion of endolymphatic stromal myosis expresses metastasis-related genes but not invasion-related matrix type metalloproteinase. Cancer Lett.112(2), 245–249 (1997).
   PubMedGoogle Scholar
• Yelian FD, Liu A, Todt JC et al. Expression and function of autocrine motility factor receptor in human choriocarcinoma. Gynecol. Oncol.62(2), 159–165 (1996).
   PubMedGoogle Scholar
• Guenther R, Krenn V, Morawietz L et al. Giant cell tumors of the bone: molecular profiling and expression analysis of Ephrin A1 receptor, Claudin 7, CD52, FGFR3 and AMFR. Pathol. Res. Pract.201(10), 649–663 (2005).
   PubMed Web of Science ®Google Scholar
• Niinaka Y, Haga A, Negishi A et al. Regulation of cell motility via high and low affinity autocrine motility factor (AMF) receptor in human oral squamous carcinoma cells. Oral Oncol.38(1), 49–55 (2002).
   PubMed Web of Science ®Google Scholar
• Goetz JG, Genty H, St-Pierre P et al. Reversible interactions between smooth domains of the endoplasmic reticulum and mitochondria are regulated by physiological cytosolic Ca2+ levels. J. Cell. Sci.120(Pt 20), 3553–3564 (2007).
   PubMed Web of Science ®Google Scholar
• Sjoblom T, Jones S, Wood LD et al. The consensus coding sequences of human breast and colorectal cancers. Science314(5797), 268–274 (2006).
   PubMed Web of Science ®Google Scholar